Skip to content

Neuronetics STIM EBITDA margin

EBITDA margin at other companies

LifeStance Health Group logo
LifeStance Health GroupLFST
6.6%+2.9pp
Stereotaxis logo
StereotaxisSTXS
-66%-14.1pp
Neuropace, Inc. logo
Neuropace, Inc.NPCE
-16.5%-3.5pp
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
26.4%+4.7pp
ClearPoint Neuro logo
ClearPoint NeuroCLPT
-63.2%-1.4pp
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
-3%-1.1pp

Other financials

Income statement

See full
Revenue$34.5M+7.8%
Gross profit$16.2M+2.6%
Operating income-$9.0M+18.3%
Net income-$10.8M+14.9%
EPS (diluted)-$0.16+23.8%

Balance sheet

See full
Cash & equivalents$13.2M-34.7%
Total debt$85.4M+3.5%
Total equity$13.3M-62.6%
Total assets$125.4M-11.7%

Cash flow

See full
Operating cash flow-$9.4M+44.6%
CapEx$197.0K-10.0%
Free cash flow-$9.6M+44.1%

Valuation

See full
Market cap$90.46M-56.2%
Enterprise value$162.64M-42.0%
P/S0.6×-1.3×

Profitability

See full
Gross margin48%-15.6pp
Operating margin-19.4%-6.9pp
Net margin-24.5%-8.7pp
FCF margin-9.4%-4.1pp

Returns & leverage

See full
Return on equity-152.4%-1.4pp
Debt / equity6.4×+4.1×
Current ratio1.7×-0.8×

Where this comes from

Calculated from Neuronetics’s reported figures.

Based on trailing twelve months.

The official record: Neuronetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuronetics's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuronetics's EBITDA margin?
Neuronetics (STIM) reported EBITDA margin of -17.2% in Q1 2026.
How has Neuronetics's EBITDA margin changed year-over-year?
Neuronetics's EBITDA margin increased by 57.6% year-over-year, from -40.6% to -17.2%.
What is the long-term trend for Neuronetics's EBITDA margin?
Over 5 years (2020 to 2025), Neuronetics's EBITDA margin has grown at a -15.4% compound annual growth rate (CAGR), from -43.4% to -18.8%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.